Anaplastic pleomorphic xanthoastrocytoma associated with an H3G34 mutation: a case report with review of literature

Brain Tumor Pathol. 2019 Oct;36(4):169-173. doi: 10.1007/s10014-019-00349-8. Epub 2019 Jul 26.

Abstract

Here, we report a rare case of anaplastic pleomorphic xanthoastrocytoma (PXA) associated with an H3G34 mutation. A 12-year-old male presented with loss of appetite, vomiting, headache, and a generalized seizure, and CT revealed a 9.0 cm left frontal lobe mass with some septal walls and a localized high-density area suggestive of hemorrhage or calcification, causing severe midline shift. He emergently underwent subtotal resection and the tumor was morphologically diagnosed as anaplastic PXA. DNA sequencing identified an H3F3A G34R mutation and a TP53 R273H mutation, and immunohistochemically, ATRX nuclear expression was lost. In CNS tumors, H3G34 mutations are essentially detected in glioblastoma (GBM) or central nervous system primitive neuroectodermal tumors. Those tumors most likely comprise a single biological entity (high-grade glioma with H3G34 mutation) because of no significant difference in molecular profiling and prognosis between GBM and PNET morphologies. To our knowledge, our present case is the first one of anaplastic PXA associated with an H3G34 mutation, and whether it biologically corresponds to "high-grade glioma with H3G34 mutation" needs further studies.

Keywords: ATRX; Anaplastic pleomorphic xanthoastrocytoma; H3G34 mutation; Olig2; TP53.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Astrocytoma / genetics*
  • Astrocytoma / pathology*
  • Biomarkers, Tumor / genetics
  • Brain Neoplasms / pathology
  • Central Nervous System Neoplasms / genetics
  • Central Nervous System Neoplasms / pathology
  • Child
  • Glioblastoma / genetics
  • Glioma / genetics
  • Humans
  • Male
  • Mutation
  • Prognosis

Substances

  • Biomarkers, Tumor